PROTAC Technology as a New Tool for Modern Pharmacotherapy

PROTAC Technology as a New Tool for Modern Pharmacotherapy

The publication focuses on the innovative applications of PROTAC (proteolysis-targeting chimera) technology in modern pharmacotherapy, with particular emphasis on cancer treatment. PROTACs represent an advanced therapeutic strategy that enables selective protein degradation, opening new possibilitie...

Full description

Saved in:

Bibliographic Details
Main Authors:	Natalia Kubryń, Łukasz Fijałkowski, Jacek Nowaczyk, Amer Jamil, Alicja Nowaczyk
Format:	Article
Language:	English
Published:	MDPI AG 2025-05-01
Series:	Molecules
Subjects:	PROTACs degradation ligands cancer
Online Access:	https://www.mdpi.com/1420-3049/30/10/2123
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Potential application of proteolysis targeting chimera (PROTAC) modification technology in natural products for their targeted protein degradation
by: Guliang Yang, et al.
Published: (2022-03-01)

Advancing Design Strategy of PROTACs for Cancer Therapy
by: Hang Luo, et al.
Published: (2025-07-01)

Design and development of PROTACs: A new paradigm in anticancer drug discovery
by: Vishal Mathur, et al.
Published: (2025-09-01)

Modeling PROTAC degradation activity with machine learning
by: Stefano Ribes, et al.
Published: (2024-12-01)

Recent advances in IAP-based PROTACs (SNIPERs) as potential therapeutic agents
by: Chao Wang, et al.
Published: (2022-12-01)

PROTACs for BRDs proteins in cancer therapy: a review
by: Chao Wang, et al.
Published: (2022-12-01)

Oligonucleotide-based PROTACs to Degrade RNA- and DNA-Binding Proteins
by: Céline N. Weller, et al.
Published: (2025-03-01)

Corrigendum to “Modeling PROTAC degradation activity with machine learning” [Artif. Intell. Life Sci. 6 (2024) 100104]
by: Stefano Ribes, et al.
Published: (2024-12-01)

Research Progress of PROTAC-Degraded CDKs in the Treatment of Breast Cancer
by: Zhao K, et al.
Published: (2025-06-01)

Indoleamine 2,3-dioxygenase 1 in cancer immunotherapy: from small-molecule inhibition to PROTAC-mediated degradation
by: Xiuyun Li, et al.
Published: (2025-08-01)

PROTAC-Based Antivirals for Respiratory Viruses: A Novel Approach for Targeted Therapy and Vaccine Development
by: Amith Anugu, et al.
Published: (2025-07-01)

Reversing TGF-β1-induced fibrotic phenotype in human lung fibroblasts using a PROTAC tool derived from an indoline-based HDAC6 inhibitor
by: Ilaria Cursaro, et al.
Published: (2025-08-01)

FDA-approved kinase inhibitors in PROTAC design, development and synthesis
by: Kacper Kossakowski, et al.
Published: (2025-12-01)

Orthogonal validation of PROTAC mediated degradation of the integral membrane proteins EGFR and c-MET
by: Camilla Ruffilli, et al.
Published: (2025-01-01)

The Peptide PROTAC Modality: A New Strategy for Drug Discovery
by: Youmin Zhu, et al.
Published: (2025-04-01)

Chemical knockdown of Keap1 and homoPROTAC-ing allergic rhinitis
by: Jianyu Yan, et al.
Published: (2025-08-01)

PROTACs: Mechanism and Bioavailability enhancement strategies by nanotechnology, RNA viral infections (vaccine strategy) and Prodrug development
by: Sanaul Mustafa, et al.
Published: (2025-01-01)

PROTACs: Mechanism and Bioavailability enhancement strategies by nanotechnology, RNA viral infections (vaccine strategy) and Prodrug development
by: Sanaul Mustafa, et al.
Published: (2025-01-01)

Development of MDM2‐Targeting PROTAC for Advancing Bone Regeneration
by: Sol Jeong, et al.
Published: (2025-05-01)

Identification of suitable target/E3 ligase pairs for PROTAC development using a rapamycin-induced proximity assay (RiPA)
by: Bikash Adhikari, et al.
Published: (2024-12-01)

Identification and removal of a cryptic impurity in pomalidomide-PEG based PROTAC
by: Bingnan Wang, et al.
Published: (2025-02-01)

PROTAC<sup>®</sup> technology and potential for its application in infection control
by: M. A. Zakharova, et al.
Published: (2024-07-01)

Targeting Stat3 with conditional knockout or PROTAC technology alleviates renal injury by Limiting pyroptosisResearch in context
by: Ming-lu Ji, et al.
Published: (2025-06-01)

Recent Advances in CBP/EP300 Degraders
by: Leonardo Palaferri, et al.
Published: (2025-03-01)

Unraveling the Engagement of Kinases to CRBN Through a Shared Structural Motif to Optimize PROTACs Efficacy
by: Serena Rosignoli, et al.
Published: (2025-02-01)

Discovery of a potent PROTAC degrader for RNA demethylase FTO as antileukemic therapy
by: Lu Liu, et al.
Published: (2024-12-01)

PROTAC Delivery Strategies for Overcoming Physicochemical Properties and Physiological Barriers in Targeted Protein Degradation
by: Endry Wahyu Syahputra, et al.
Published: (2025-04-01)

MEGA PROTAC, MEGA DOCK-based PROTAC mediated ternary complex formation pipeline with sequential filtering and rank aggregation
by: Sadettin Y. Ugurlu, et al.
Published: (2025-02-01)

Self-assembled PROTACs enable protein degradation to reprogram the tumor microenvironment for synergistically enhanced colorectal cancer immunotherapy
by: Xinchen Lu, et al.
Published: (2025-01-01)

A pH-responsive PROTAC-based nanosystem triggers tumor-specific ferroptosis to construct in situ tumor vaccines
by: Linghong Huang, et al.
Published: (2025-04-01)

Advances in KEAP1-based PROTACs as emerging therapeutic modalities: Structural basis and progress
by: Jing Chen, et al.
Published: (2025-09-01)

Design, synthesis, and molecular docking studies of novel pomalidomide-based PROTACs as potential anti-cancer agents targeting EGFRWT and EGFRT790M
by: Moustafa O. Aboelez, et al.
Published: (2022-12-01)

BRAFV600E‐PROTAC versus inhibitors in melanoma cells: Deep transcriptomic characterization
by: Solomon O. Alhassan, et al.
Published: (2025-03-01)

YX-112, a novel celastrol-derived PROTAC, inhibits the development of triple-negative breast cancer by targeting the degradation of multiple proteins
by: Yongxue Gu, et al.
Published: (2025-04-01)

Innovative PDK1‐Degrading PROTACs Transform Cancer Aerobic Glycolysis and Induce Immunogenic Cell Death in Breast Cancer
by: Aohua Deng, et al.
Published: (2025-08-01)

Discovery of a potential hematologic malignancies therapy: Selective and potent HDAC7 PROTAC degrader targeting non-enzymatic function
by: Yuheng Jin, et al.
Published: (2025-03-01)

SGLT2 Inhibitors: From Molecular Mechanisms to Clinical Outcomes in Cardiology and Diabetology
by: Marlena Stielow, et al.
Published: (2025-07-01)

PROTAC‐Mediated HDAC7 Protein Degradation Unveils Its Deacetylase‐Independent Proinflammatory Function in Macrophages
by: Kailibinuer Kadier, et al.
Published: (2024-09-01)

ProLinker–Generator: Design of a PROTAC Linker Base on a Generation Model Using Transfer and Reinforcement Learning
by: Yanlin Luo, et al.
Published: (2025-05-01)

Targeted degradation of extracellular proteins: state of the art and diversity of degrader designs
by: M. A. A. Mamun, et al.
Published: (2025-05-01)